☆ 4.5 Article

Neutralizing antibody responses 300 days after SARS-CoV-2 infection and induction of high antibody titers after vaccination

EUROPEAN JOURNAL OF IMMUNOLOGY (2022)

Related references

Note: Only part of the references are listed.

Article Immunology

Large-Scale Study of Antibody Titer Decay following BNT162b2 mRNA Vaccine or SARS-CoV-2 Infection

Ariel Israel et al.

Summary: This study demonstrates that individuals who received the Pfizer-BioNTech mRNA vaccine have higher initial levels of antibodies compared to patients who had been infected with the SARS-CoV-2 virus, but experience a much faster exponential decrease in antibody levels.

VACCINES (2022)

Add to Collection

Article Immunology

SARS-CoV-2 infection shortly after BNT162b2 vaccination results in high anti-spike antibody levels in nursing home residents and staff

Doris Urlaub et al.

Summary: The study found that individuals who were infected as early as 10 days after their first vaccine dose had antibody levels comparable to fully vaccinated individuals.

IMMUNITY INFLAMMATION AND DISEASE (2021)

Add to Collection

Article Multidisciplinary Sciences

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Jennifer M. Dan et al.

Summary: Different components of immune memory to SARS-CoV-2 exhibit distinct kinetics, with antibodies and spike-specific memory B cells remaining relatively stable over 6 months, while CD4(+) T cells and CD8(+) T cells declining with a half-life of 3 to 5 months after infection.

SCIENCE (2021)

Add to Collection

Letter Medicine, General & Internal

Durability of Antibody Levels After Vaccination With mRNA SARS-CoV-2 Vaccine in Individuals With or Without Prior Infection

Diana Zhong et al.

Summary: This study compares the durability of antibodies in individuals who received mRNA SARS-CoV-2 vaccine with prior infection and those without infection.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Medicine, General & Internal

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

Sara Y. Tartof et al.

Summary: This study aimed to assess the overall and variant-specific effectiveness of the BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19-related hospital admissions among members of a healthcare system in California. The effectiveness of the vaccine remained high against hospital admissions even up to 6 months after full vaccination, despite a decline in effectiveness against SARS-CoV-2 infections over time, which was likely due to waning immunity rather than the delta variant escaping vaccine protection.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Waning Immunity after the BNT162b2 Vaccine in Israel

Yair Goldberg et al.

Summary: The immunity against the delta variant of SARS-CoV-2 waned in all age groups in Israel a few months after receiving the second dose of the vaccine, leading to an increase in infection and severe cases.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar

Hiam Chemaitelly et al.

Summary: In a study conducted in Qatar involving over 900,000 participants, vaccine effectiveness peaked at 77.5% in the first month after the second dose. However, it declined afterwards to as low as 20% in months 5 through 7 after vaccination, while protection against severe Covid-19 remained above 90% for at least 6 months.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine

Florian Krammer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Anti-spike antibody response to natural SARS-CoV-2 infection in the general population

Jia Wei et al.

Summary: Understanding antibody responses after SARS-CoV-2 infection is crucial for assessing protection and risk of reinfection. This study, using representative data from the UK, found that 24% of participants did not develop anti-spike antibodies, with older participants and those of non-white ethnicity having higher peak antibody levels. The estimated antibody levels associated with protection against reinfection may last 1.5-2 years on average.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Microbiology

Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans

Kanika Vanshylla et al.

Summary: The study reveals a wide spectrum of neutralizing antibody response to SARS-CoV-2, with sustained antibodies in the majority of individuals with mild COVID-19 for up to 10 months after infection.

CELL HOST & MICROBE (2021)

Add to Collection

Letter Critical Care Medicine

Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers

Pinkus Tober-Lau et al.

LANCET RESPIRATORY MEDICINE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

David S. Khoury et al.

Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.

NATURE MEDICINE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2

Fatima Amanat et al.

Summary: After receiving the SARS-CoV-2 spike mRNA vaccine, individuals showed robust polyclonal antibody responses, with a majority of vaccine-induced antibodies lacking neutralizing activity. However, vaccine-induced RBD binding antibodies may offer substantial protection against viral variants carrying single E484K RBD mutations.

CELL (2021)

Add to Collection

Article Immunology

Evidence for antibody as a protective correlate for COVID-19 vaccines

Kristen A. Earle et al.

Summary: The study found a strong correlation between antibody titers and efficacy when assessing different COVID-19 vaccines, supporting the use of post-immunization antibody titers as the basis for establishing a correlate of protection for COVID-19 vaccines.

VACCINE (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance — Eight U.S. Locations, December 2020–August 2021

Ashley Fowlkes et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021

Wesley H. Self et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Article Biochemistry & Molecular Biology

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Markus Hoffmann et al.

CELL (2020)

Add to Collection

Article Multidisciplinary Sciences

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Ania Wajnberg et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

A Vesicular Stomatitis Virus Replicon-Based Bioassay for the Rapid and Sensitive Determination of Multi-Species Type I Interferon

Marianne Berger Rentsch et al.

PLOS ONE (2011)

Add to Collection

Article Biochemical Research Methods

Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines

Michael A. Whitt

JOURNAL OF VIROLOGICAL METHODS (2010)

Add to Collection

© Peeref 2019-2024. All rights reserved.